Arnold Jason W, Whittington Hunter D, Dagher Suzanne F, Roach Jeffery, Azcarate-Peril M Andrea, Bruno-Barcena Jose M
Division of Gastroenterology and Hepatology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, United States.
UNC Microbiome Core, Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, Chapel Hill, NC, United States.
Front Nutr. 2021 Apr 7;8:640100. doi: 10.3389/fnut.2021.640100. eCollection 2021.
Complex dietary carbohydrate structures including β(1-4) galacto-oligosaccharides (GOS) are resistant to digestion in the upper gastrointestinal (GI) tract and arrive intact to the colon where they benefit the host by selectively stimulating microbial growth. Studies have reported the beneficial impact of GOS (alone or in combination with other prebiotics) by serving as metabolic substrates for modulating the assembly of the infant gut microbiome while reducing GI infections. N-Acetyl-D-lactosamine (LacNAc, Galβ1,4GlcNAc) is found in breast milk as a free disaccharide. This compound is also found as a component of human milk oligosaccharides (HMOs), which have repeating and variably branched lactose and/or LacNAc units, often attached to sialic acid and fucose monosaccharides. Human glycosyl-hydrolases do not degrade most HMOs, indicating that these structures have evolved as natural prebiotics to drive the proper assembly of the infant healthy gut microbiota. Here, we sought to develop a novel enzymatic method for generating LacNAc-enriched GOS, which we refer to as humanized GOS (hGOS). We showed that the membrane-bound β-hexosyl transferase (rBHT) from was able to generate GOS and hGOS from lactose and N-Acetyl-glucosamine (GlcNAc). The enzyme catalyzed the regio-selective, repeated addition of galactose from lactose to GlcNAc forming the β-galactosyl linkage at the 4-position of the GlcNAc and at the 1-position of D-galactose generating, in addition to GOS, LacNAc, and Galactosyl-LacNAc trisaccharides which were produced by two sequential transgalactosylations. Humanized GOS is chemically distinct from HMOs, and its effects have yet to be determined. Thus, we evaluated its safety and demonstrated the prebiotic's ability to modulate the gut microbiome in 6-week-old C57BL/6J mice. Longitudinal analysis of gut microbiome composition of stool samples collected from mice fed a diet containing hGOS for 5 weeks showed a transient reduction in alpha diversity. Differences in microbiome community composition mostly within the phylum were observed between hGOS and GOS, compared to control-fed animals. In sum, our study demonstrated the biological synthesis of hGOS, and signaled its safety and ability to modulate the gut microbiome , promoting the growth of beneficial microorganisms, including and .
包括β(1-4)低聚半乳糖(GOS)在内的复杂膳食碳水化合物结构在上消化道(GI)中不易被消化,并完整地到达结肠,在那里它们通过选择性刺激微生物生长而使宿主受益。研究报告了GOS(单独或与其他益生元联合使用)作为代谢底物对调节婴儿肠道微生物群组装同时减少胃肠道感染的有益影响。N-乙酰-D-乳糖胺(LacNAc,Galβ1,4GlcNAc)在母乳中以游离二糖形式存在。该化合物也作为人乳寡糖(HMOs)的组成成分被发现,HMOs具有重复且分支可变的乳糖和/或LacNAc单元,通常连接到唾液酸和岩藻糖单糖上。人类糖基水解酶不会降解大多数HMOs,这表明这些结构已进化为天然益生元以驱动婴儿健康肠道微生物群的正确组装。在此,我们试图开发一种新的酶法来生成富含LacNAc的GOS,我们将其称为人源化GOS(hGOS)。我们发现来自[具体来源未明确]的膜结合β-己糖基转移酶(rBHT)能够从乳糖和N-乙酰葡糖胺(GlcNAc)生成GOS和hGOS。该酶催化乳糖中的半乳糖区域选择性地重复添加到GlcNAc上,在GlcNAc的4位和D-半乳糖的1位形成β-半乳糖苷键,除了生成GOS外,还生成LacNAc以及由两次连续转半乳糖基化产生的半乳糖基-LacNAc三糖。人源化GOS在化学上与HMOs不同,其效果尚未确定。因此,我们评估了其安全性,并证明了这种益生元在6周龄C57BL/6J小鼠中调节肠道微生物群的能力。对喂食含hGOS饮食5周的小鼠收集的粪便样本进行肠道微生物群组成的纵向分析显示,α多样性短暂降低。与对照喂养的动物相比,在hGOS和GOS之间观察到微生物群落组成的差异,主要在[具体门类未明确]门内。总之,我们的研究证明了hGOS的生物合成,并表明了其安全性以及调节肠道微生物群的能力,促进了包括[具体微生物未明确]和[具体微生物未明确]在内的有益微生物的生长。